These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19818359)

  • 1. Nucleophosmin in the pathogenesis of arsenic-related bladder carcinogenesis revealed by quantitative proteomics.
    Chen SH; Wang YW; Hsu JL; Chang HY; Wang CY; Shen PT; Chiang CW; Chuang JJ; Tsai HW; Gu PW; Chang FC; Liu HS; Chow NH
    Toxicol Appl Pharmacol; 2010 Jan; 242(2):126-35. PubMed ID: 19818359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of gene expression profiles in HepG2 cells exposed to arsenic, cadmium, nickel, and three model carcinogens for investigating the mechanisms of metal carcinogenesis.
    Kawata K; Shimazaki R; Okabe S
    Environ Mol Mutagen; 2009 Jan; 50(1):46-59. PubMed ID: 19031421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of interspecies concordance of mechanisms of arsenic-induced bladder cancer.
    Sen B; Wolf DC; Turpaz Y; Bugrim A; Retief J; Hester SD
    Toxicol In Vitro; 2007 Dec; 21(8):1513-29. PubMed ID: 17720352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
    Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
    Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment.
    Nagano K; Shinkawa T; Mutoh H; Kondoh O; Morimoto S; Inomata N; Ashihara M; Ishii N; Aoki Y; Haramura M
    Proteomics; 2009 May; 9(10):2861-74. PubMed ID: 19415658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic analysis of immature murine melanocytes at different stages of maturation: a crucial role for calreticulin.
    Kawase A; Kushimoto T; Kawa Y; Ohsumi K; Nishikawa H; Kawakami T; Mizoguchi M; Soma Y
    J Dermatol Sci; 2008 Jan; 49(1):43-52. PubMed ID: 17826037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers.
    Lund R; Leth-Larsen R; Jensen ON; Ditzel HJ
    J Proteome Res; 2009 Jun; 8(6):3078-90. PubMed ID: 19341246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomics analysis of two mice hepatocarcinoma ascites syngeneic cell lines with high and low lymph node metastasis rates provide potential protein markers for tumor malignancy attributes to lymphatic metastasis.
    Sun MZ; Liu S; Tang J; Wang Z; Gong X; Sun C; Greenaway F
    Proteomics; 2009 Jun; 9(12):3285-302. PubMed ID: 19562801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for toxicity differences between inorganic arsenite and thioarsenicals in human bladder cancer cells.
    Naranmandura H; Ogra Y; Iwata K; Lee J; Suzuki KT; Weinfeld M; Le XC
    Toxicol Appl Pharmacol; 2009 Jul; 238(2):133-40. PubMed ID: 19442679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells.
    Jian Y; Gao Z; Sun J; Shen Q; Feng F; Jing Y; Yang C
    Oncogene; 2009 Nov; 28(47):4201-11. PubMed ID: 19734942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative proteomics using formalin-fixed paraffin-embedded tissues of oral squamous cell carcinoma.
    Negishi A; Masuda M; Ono M; Honda K; Shitashige M; Satow R; Sakuma T; Kuwabara H; Nakanishi Y; Kanai Y; Omura K; Hirohashi S; Yamada T
    Cancer Sci; 2009 Sep; 100(9):1605-11. PubMed ID: 19522851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms?
    Simeonova PP; Luster MI
    J Environ Pathol Toxicol Oncol; 2000; 19(3):281-6. PubMed ID: 10983894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis of the nuclear matrix in the early stages of rat liver carcinogenesis: identification of differentially expressed and MAR-binding proteins.
    Barboro P; D'Arrigo C; Repaci E; Bagnasco L; Orecchia P; Carnemolla B; Patrone E; Balbi C
    Exp Cell Res; 2009 Jan; 315(2):226-39. PubMed ID: 19000672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immortalized human urothelial cells as a model of arsenic-induced bladder cancer.
    Eblin KE; Bredfeldt TG; Gandolfi AJ
    Toxicology; 2008 Jun; 248(2-3):67-76. PubMed ID: 18456381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer.
    Makridakis M; Gagos S; Petrolekas A; Roubelakis MG; Bitsika V; Stravodimos K; Pavlakis K; Anagnou NP; Coleman J; Vlahou A
    Proteomics; 2009 Jan; 9(2):287-98. PubMed ID: 19105184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms.
    Eriksson H; Lengqvist J; Hedlund J; Uhlén K; Orre LM; Bjellqvist B; Persson B; Lehtiö J; Jakobsson PJ
    Proteomics; 2008 Aug; 8(15):3008-18. PubMed ID: 18654985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted quantitative mass spectrometric identification of differentially expressed proteins between Bax-expressing and deficient colorectal carcinoma cells.
    Wang P; Lo A; Young JB; Song JH; Lai R; Kneteman NM; Hao C; Li L
    J Proteome Res; 2009 Jul; 8(7):3403-14. PubMed ID: 19425606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-dimensional electrophoretic protein profile analysis following exposure of human uroepithelial cells to occupational bladder carcinogens.
    Kanitz MH; Swaminathan S; Savage RE
    Cancer Lett; 2004 Mar; 205(2):121-31. PubMed ID: 15036644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer.
    Aggarwal S; He T; Fitzhugh W; Rosenthal K; Feild B; Heidbrink J; Mesmer D; Ruben SM; Moore PA
    Gynecol Oncol; 2009 Dec; 115(3):430-7. PubMed ID: 19800108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases.
    Colombo E; Alcalay M; Pelicci PG
    Oncogene; 2011 Jun; 30(23):2595-609. PubMed ID: 21278791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.